Complete Genomics Inc. Board of Directors Under Investigation for Potential Breaches of Fiduciary Duty by Glancy Binkow & Gol...
September 17 2012 - 6:00PM
Business Wire
Glancy Binkow & Goldberg LLP announces that it is
investigating potential claims against the Board of Directors of
Complete Genomics Inc. (“Complete Genomics” or the “Company”)
(NASDAQ: GNOM) related to the proposed acquisition of the Company
by BGI-Shenzhen. The transaction is valued at approximately $117.6
million or $3.15 per share.
This investigation concerns whether the Board of Directors of
Complete Genomics breached their fiduciary duties to stockholders
by failing to adequately shop the Company before agreeing to enter
into the proposed transaction, and whether the Company has
disclosed all material information to shareholders about the
transaction. The Company has seen substantial recent growth. Its
share price has skyrocketed from $1.82 on June 28, 2012 to $3.15 on
September 7, 2012. Further, at least one analyst has set a target
price for the Company’s stock at $5.00.
If you are a shareholder of Complete Genomics, if you have
information or would like to learn more about our investigation, or
if you wish to discuss these matters or have any questions
concerning this announcement or your rights or interests with
respect to these matters, please contact Louis Boyarsky, Esquire,
Glancy Binkow & Goldberg LLP, 1925 Century Park East, Suite
2100, Los Angeles, CA 90067, by telephone at (310) 201-9150 or Toll
Free at (888) 773-9224 or by email to
shareholders@glancylaw.com.
This press release may be considered Attorney Advertising in
some jurisdictions under the applicable law and ethical rules.
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Jul 2023 to Jul 2024